ICR hails ‘momentous’ recommendation of olaparib for breast and prostate cancer 05 Apr 2023 The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer. Find out more Show/Hide
Prostate cancer drug targeting Achilles heel approved in Europe 06 Nov 2020 The Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in BRCA1 or BRCA2. Find out more Show/Hide
ESMO 2020: Breast cancer drug set to transform prostate cancer treatment 20 Sep 2020 A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice. Find out more Show/Hide
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019